Literature DB >> 12658908

Clinicopathologic profile of gestational trophoblastic disease.

Darko Jelincic1, Gernot Hudelist, Christian Fridolin Singer, Margit Bauer, Lars Christian Horn, Karin Bilek, Klaus Czerwenka.   

Abstract

Much debate exists on factors predicting the development of persistent gestational trophoblastic disease (pGTD). Diagnosis is still limited by following persistently elevated or rising postevacutation beta-human chorionic gonadotropin (beta-hCG) titers. The aim of the present work was to evaluate the hypothesis that the presence of c-erbB-2 oncogene amplification and expression, in combination with parameters such as DNA-content and karyotype of the sex chromosomes, confer an increased risk of developing pGTD. Clinicopathological characteristics were evaluated in 36 cases of gestational trophoblastic diseases (GTD) and analyzed for c-erbB-2 amplification and protein p185 expression using differential polymerase chain reaction (DPCR) and immunohistochemical (IHC) techniques. The DNA-content was determined by image analysis on Feulgen stained nuclear cell preparations and karyotyping for XY chromosomes was performed by fluorescence in situ hybridization (FISH). The data was correlated with histopathological characteristics of GTD. Seventy-five percent (n = 27) of the examined cases showed spontaneous regression after evacuation, including 2 patients who received additional chemotherapy. Twenty-five percent (n = 9) resulted in a persistent or metastatic disease. The median time between antecedent pregnancy and GTD was 45.4 months. Complete remission was achieved in all patients with pGTD after administration of chemotherapeutic agents or adjuvant surgical procedures. Cases with cerbB-2 amplification and expression in combination with DNA hyperploidy showed higher proliferation and more aggressive behavior (2 complete hydatidiform moles with lung and liver metastases, 2 invasive moles and 1 choriocarcinoma). XY karyotype was evident in the choriocarcinoma and in 2 complete hydatidiform moles with advanced stage and DNA hyperploidy. From these results we conclude that c-erbB-2 amplification and/or protein expression in combination with DNA-content show a significant correlation with the proliferative and aggressive potential of GTD, suggesting their combined use as a possible marker for pGTD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12658908     DOI: 10.1007/BF03040269

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  36 in total

1.  Flow cytometric analysis of nuclear DNA content in gestational trophoblastic disease.

Authors:  J M Lage
Journal:  J Reprod Med       Date:  1991-01       Impact factor: 0.142

Review 2.  Genetic analysis of gestational trophoblastic disease: a review.

Authors:  N G Wolf; J M Lage
Journal:  Semin Oncol       Date:  1995-04       Impact factor: 4.929

3.  Application of flow cytometry in diagnosis of hydatidiform moles.

Authors:  M Fukunaga; S Ushigome; M Fukunaga; M Sugishita
Journal:  Mod Pathol       Date:  1993-05       Impact factor: 7.842

4.  Fluorescent in situ hybridization assessment of chromosome copy number in gestational trophoblastic disease.

Authors:  H F Mark; M G Grollino; R A Sulaiman; J C Lathrop
Journal:  Ann Clin Lab Sci       Date:  1995 Jul-Aug       Impact factor: 1.256

5.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

6.  c-myc, c-erbB-2, c-fms and bcl-2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma.

Authors:  V Fulop; S C Mok; D R Genest; I Szigetvari; I Cseh; R S Berkowitz
Journal:  J Reprod Med       Date:  1998-02       Impact factor: 0.142

7.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

8.  Malignant potential of homozygous and heterozygous complete moles.

Authors:  N Wake; T Seki; H Fujita; H Okubo; K Sakai; K Okuyama; H Hayashi; Y Shiina; H Sato; M Kuroda
Journal:  Cancer Res       Date:  1984-03       Impact factor: 12.701

9.  Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.

Authors:  A Berchuck; A Kamel; R Whitaker; B Kerns; G Olt; R Kinney; J T Soper; R Dodge; D L Clarke-Pearson; P Marks
Journal:  Cancer Res       Date:  1990-07-01       Impact factor: 12.701

10.  Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer.

Authors:  C Wright; S Nicholson; B Angus; J R Sainsbury; J Farndon; J Cairns; A L Harris; C H Horne
Journal:  Br J Cancer       Date:  1992-01       Impact factor: 7.640

View more
  4 in total

1.  [Gestational trophoblastic disease, Villous gestational trophoblastic disease].

Authors:  M Vogel; L-C Horn
Journal:  Pathologe       Date:  2004-07       Impact factor: 1.011

Review 2.  Unexplained anaemia and failure to thrive as initial symptoms of infantile choriocarcinoma: a review.

Authors:  Martin E G Blohm; Ulrich Göbel
Journal:  Eur J Pediatr       Date:  2003-11-20       Impact factor: 3.183

3.  Immunohistochemistry Study of P53 and C-erbB-2 Expression in Trophoblastic Tissue and Their Predictive Values in Diagnosing Malignant Progression of Simple Molar Pregnancy.

Authors:  Malihe Hasanzadeh; Norrie Sharifi; Marjaneh Farazestanian; Seyed Saman Nazemian; Faezeh Madani Sani
Journal:  Iran J Cancer Prev       Date:  2016-06-13

4.  Gene amplification during myogenic differentiation.

Authors:  Ulrike Fischer; Nicole Ludwig; Abdulrahman Raslan; Carola Meier; Eckart Meese
Journal:  Oncotarget       Date:  2016-02-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.